Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus

Alvarez Maturell Elvio Luis; Pérez Parrado Ileana; Pérez Parrado Rogelio

doi:doi:10.11648/j.iji.20221003.11

| Peer-Reviewed

Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus

Alvarez Maturell Elvio Luis, Pérez Parrado Ileana, Pérez Parrado Rogelio

Published in International Journal of Immunology (Volume 10, Issue 3)

Received: 14 December 2021 Accepted: 15 January 2022 Published: 17 October 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Dengue is an acute fever disease of sudden beginning, which is characterized by fever, cefalea, arthralgia, myalgia, rash, nausea, vomits and is caused by the Dengue virus that belongs to the Flaviviridae family, flavivirus genre and has four viral serotypes DEN -1, DEN - 2, DEN - 3, DEN – 4. It is transmitted by female mosquito bites from the Aedes aegypti genre and the A. albopictus. Medically, it constitutes the most important viral disease transmitted by anthropoid and the most important in terms of morbidity and mortality. Therefore, it is more important to assess the detection of antibodies IgM Dengue with immune enzymatic test UMELISA IgM Dengue plus in the surveillance of Dengue. Material and Methods: An observational study of transversal type was done from January to December 2017 in SUMA Laboratory of Advance Technology Hygiene, Epidemiology and Microbiology Provincial Center of Ciego de Ávila, Cuba to samples of specimen of serum that were collected from people with SFI from the 6^th day of the beginning of symptoms to detect antibodies IgM against Dengue using immune enzymatic test UMELISA IgM Dengue plus. Results: The results are represented in graphs from January to December 2017. Conclusions: The month of greater reactivity was October with 25.99% and the municipalities more affected were Baraguá with 20%, Ciego de Ávila with 11.99%, Morón with 11.86%, and Ciro Redondo with 11.11% of reactivity which were municipalities with transmission. The positive and negative control serum of the test was under statistic control. The concordance between the tests was 86.60% and the prevalence for the UMELISA IgM DENGUE PLUS test was 10.32%.

Published in	International Journal of Immunology (Volume 10, Issue 3)
DOI	10.11648/j.iji.20221003.11
Page(s)	25-29
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Dengue Survillance, UMELISA IgM PLUS DENGUE, ELISA IgM MAC, Unspecific Fever Symptoms

References

[1]	Sandoval VJH, Amores RD, Ranudo VS, Gutirrez CN, Tirado GMG. Evaluación del sistema diagnóstico SD DENGUE DUO para la detección de la proteína NS1 y los anticuerpos IgM e IgG anti dengue. Rev Cubana Med Trop. 2012; 64 (1): 27-4.
[2]	Rivera AH, Rodríguez AP, Meléndrez EH. Aspectos de importancia clínica del dengue en la comunidad de San Mateo, Anzoátegui, Venezuela (2005-2008). Rev Cubana Med Gen Integr 2011; 27 (4).
[3]	Rivera AH, Rodríguez AP. Estudio seroepidemiológico de infección de dengue en San Mateo, Anzoátegui, Venezuela 2007-2008. Rev Panam Infectol. 2010; 12 (3): 33-8.
[4]	Ávila-Agüero ML. Dengue. Acta Méd. Costarric [serieen Internet]. 2008 septiembre [Consultado: 20 de mayo de 2011]; 50 (3): 128-30. Disponibleen: http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S0001-60022008000300001&lng=es
[5]	Rivera AH, Rodríguez AP, Meléndrez EH. Espectro clínico del dengue. Rev Cubana Med. 2012; 51 (1): 61-8.
[6]	Alfonso Calderón E, Blanco Berta L. La enfermedad de dengue en colaboradores cubanos en el estado de Nueva Esparta. Año 2007. Rev Méd Electrón. [Seriadaenlínea] 2010; 32 (3). [citado 16 de mayo de 2011.] Disponibleen: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1684-18242010000300003&lng=es&nrm=iso&tlng=es
[7]	Salud R, Martínez A, Alexander Díaz F, Villa LA. Evaluación de la definición clínica de dengue sugerida por la Organización Mundial de la Salud. Centro de Investigaciones Epidemiológicas, Facultad de Salud, Universidad Industrial de Santander, Bucaramanga, Colombia. [Citado: septiembre 2009.] Disponibleen: http://www.ops.org.bo/textocompleto/rib250001.pdf
[8]	Martinez E. Medical Care Organization to Face Dengue Epidemics. Rev Cubana Med Trop [revista en Internet]. 2009 Ago [citado13 de abril de 2010]; 61 (2). Disponibleen: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375-07602009000200001&lng=es
[9]	Jaenisch T, Wills B. Results from the DENCO study. TDR/WHO Expert Meeting on Dengue Classification and Case Management. Implications of the DENCO study. WHO, Geneve, Sep 30-Oct 1/2008. [citado 2 de mayo de 2011]. Disponibleen: http://www.medicinaysociedad.org.ar/publicaciones/marzo_2010/REC 367 - Especial Acciones desarrolladas contra el Dengue en el IPEM 54 de Oncativo.pdf
[10]	Guzmán MG, Kouri G. Dengue: an update. Lancet Infect Dis. 2002; 2 (1): 33-42.
[11]	Posada FP, Ferrer MY, Rodríguez VIM. Caracterización epidemiológica del dengue en Ciego de Ávila. MEDICIEGO. 210; 16 (Supl. 1).
[12]	Marco J, Cabrera A. Actualización sobre el dengue como enfermedad reemergente, para evitar que sea permanente. Experiencia cubana. 2006 junio [Consultado: 12 de abril de 2010]. Disponibleen: http://www.portalesmedicos.com.
[13]	Posada FPE, Retureta MME, Rodríguez VIM, Godoy MD, López GG. Propuesta metodológica para estratificar el riesgo de transmisión de dengue en situaciones de epidemia. MEDICIEGO 2013; 19 (No. 2).
[14]	Kourí G. El dengue, un problema creciente de salud en las Américas. Rev Cubana Salud Pública. 2011; 37 (supl. 5).
[15]	Valdivia I, Palenzuela A, Herrera R. Umelisa dengue plus: una nueva herramienta para el diagnóstico y la vigilancia epidemiológica comunitaria. Centro de Inmunoensayo. 2006 [Consultado: septiembre de 2009] Disponibleen: http://www.forumcyt.cu/UserFiles/forum/Textos/0303648.pdf.
[16]	Buchy F, Yoksan S, Peeling RW, Hunsperger E. Laboratory tests for the diagnosis of dengue virus infection. Geneva, Switzerland: TRD/ Scientific Working Group; 2006. p. 74-85.
[17]	Young PR, Hilditch PA, Bletchly C, Halloran W. An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J ClinMicrobiol. 2000; 38 (3): 1053-7.
[18]	Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, Flamand M. Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J ClinMicrobiol. 2002; 40 (2): 376-81.
[19]	Vázquez S, Ruiz D, Barrero R, Ramírez R, Calzada N, Del Rosario Peña B, et al. Kinetics of dengue virus NS1 protein in dengue 4-confirmed adult patients. Diagnostic Microbiology Infectious Disease. 2010; 68 (46-9).
[20]	Bessoff K, Phoutrides E, Delorey M, Acosta L, Hunsperger E. Utility of a commercial nonstructural protein 1 antigen capture kit as a dengue virus diagnostic tool. Clin Vaccine Immunol. 2010; 17 (6): 949-53.
[21]	Guzmán MG, Jaenisch T, Gaczkowski R, Ty Hang VT, Sekaran SD, Kroeger A, et al. Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoSNegl Trop Dis. 2010; 4 (8): e811.
[22]	Tricou V, Vu HT, Quynh NV, Nguyen CV, Tran HT, Farrar J, et al. Comparison of two dengue NS1 rapid tests for sensitivity, specificity and relationship to viraemia and antibody responses. BMC Infect Dis 2010; 10: 142.
[23]	Hang VT, Nguyet NM, Trung DT, Tricou V, Yoksan S, Dung NM, et al. Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. PLoSNegl Trop Dis. 2009; 3 (1): e360.
[24]	Vázquez S, Cabezas S, Perez AB, Pupo M, Ruiz D, Calzada N, et al. Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections. Int J Infect Dis. 2007; 11 (3): 256-62.
[25]	Vázquez S, Acosta N, Ruiz D, Calzada N, Alvarez AM, Guzman MG. Immunoglobulin G antibody response in children and adults with acute dengue 3 infection. J VirolMethods. 2009; 159 (1): 6-9.
[26]	Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, et al. Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis. 2009; 15 (3): 436-40.
[27]	Dussart P, Petit L, Labeau B, Bremand L, Leduc A, Moua D, et al. Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. PLoSNegl Trop Dis. 2008; 2 (8): e280.
[28]	Dussart P, Labeau B, Lagathu G, Louis P, Nunes MR, Rodrigues SG, et al. Evaluation of an enzyme immunoassay for detection of dengue virus NS1 antigen in human serum. Clin Vaccine Immunol. 2006; 13 (11): 1185-9.
[29]	Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002; 186 (8): 1165-8.
[30]	Blacksell SD, Doust JA, Newton PN, Peacock SJ, Day NP, Dondorp AM. A systematic review and meta-analysis of the diagnostic accuracy of rapid immunochromatographic assays for the detection of dengue virus IgM antibodies during acute infection. Trans R Soc Trop Med Hyg. 2006; 100 (8): 775-84.
[31]	Nga TT, Thai KT, Phuong HL, Giao PT, Hung Le Q, Binh TQ, et al. Evaluation of two rapid immunochromatographic assays for diagnosis of dengue among Vietnamese febrile patients. Clin Vaccine Immunol. 2007; 14 (6): 799-801.

Cite This Article

Plain Text BibTeX RIS

APA Style

Alvarez Maturell Elvio Luis, Pérez Parrado Ileana, Pérez Parrado Rogelio. (2022). Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus. International Journal of Immunology, 10(3), 25-29. https://doi.org/10.11648/j.iji.20221003.11

Copy | Download

ACS Style

Alvarez Maturell Elvio Luis; Pérez Parrado Ileana; Pérez Parrado Rogelio. Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus. Int. J. Immunol. 2022, 10(3), 25-29. doi: 10.11648/j.iji.20221003.11

Copy | Download

AMA Style

Alvarez Maturell Elvio Luis, Pérez Parrado Ileana, Pérez Parrado Rogelio. Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus. Int J Immunol. 2022;10(3):25-29. doi: 10.11648/j.iji.20221003.11

Copy | Download

@article{10.11648/j.iji.20221003.11,
  author = {Alvarez Maturell Elvio Luis and Pérez Parrado Ileana and Pérez Parrado Rogelio},
  title = {Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus},
  journal = {International Journal of Immunology},
  volume = {10},
  number = {3},
  pages = {25-29},
  doi = {10.11648/j.iji.20221003.11},
  url = {https://doi.org/10.11648/j.iji.20221003.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20221003.11},
  abstract = {Introduction: Dengue is an acute fever disease of sudden beginning, which is characterized by fever, cefalea, arthralgia, myalgia, rash, nausea, vomits and is caused by the Dengue virus that belongs to the Flaviviridae family, flavivirus genre and has four viral serotypes DEN -1, DEN - 2, DEN - 3, DEN – 4. It is transmitted by female mosquito bites from the Aedes aegypti genre and the A. albopictus. Medically, it constitutes the most important viral disease transmitted by anthropoid and the most important in terms of morbidity and mortality. Therefore, it is more important to assess the detection of antibodies IgM Dengue with immune enzymatic test UMELISA IgM Dengue plus in the surveillance of Dengue. Material and Methods: An observational study of transversal type was done from January to December 2017 in SUMA Laboratory of Advance Technology Hygiene, Epidemiology and Microbiology Provincial Center of Ciego de Ávila, Cuba to samples of specimen of serum that were collected from people with SFI from the 6th day of the beginning of symptoms to detect antibodies IgM against Dengue using immune enzymatic test UMELISA IgM Dengue plus. Results: The results are represented in graphs from January to December 2017. Conclusions: The month of greater reactivity was October with 25.99% and the municipalities more affected were Baraguá with 20%, Ciego de Ávila with 11.99%, Morón with 11.86%, and Ciro Redondo with 11.11% of reactivity which were municipalities with transmission. The positive and negative control serum of the test was under statistic control. The concordance between the tests was 86.60% and the prevalence for the UMELISA IgM DENGUE PLUS test was 10.32%.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus
AU  - Alvarez Maturell Elvio Luis
AU  - Pérez Parrado Ileana
AU  - Pérez Parrado Rogelio
Y1  - 2022/10/17
PY  - 2022
N1  - https://doi.org/10.11648/j.iji.20221003.11
DO  - 10.11648/j.iji.20221003.11
T2  - International Journal of Immunology
JF  - International Journal of Immunology
JO  - International Journal of Immunology
SP  - 25
EP  - 29
PB  - Science Publishing Group
SN  - 2329-1753
UR  - https://doi.org/10.11648/j.iji.20221003.11
AB  - Introduction: Dengue is an acute fever disease of sudden beginning, which is characterized by fever, cefalea, arthralgia, myalgia, rash, nausea, vomits and is caused by the Dengue virus that belongs to the Flaviviridae family, flavivirus genre and has four viral serotypes DEN -1, DEN - 2, DEN - 3, DEN – 4. It is transmitted by female mosquito bites from the Aedes aegypti genre and the A. albopictus. Medically, it constitutes the most important viral disease transmitted by anthropoid and the most important in terms of morbidity and mortality. Therefore, it is more important to assess the detection of antibodies IgM Dengue with immune enzymatic test UMELISA IgM Dengue plus in the surveillance of Dengue. Material and Methods: An observational study of transversal type was done from January to December 2017 in SUMA Laboratory of Advance Technology Hygiene, Epidemiology and Microbiology Provincial Center of Ciego de Ávila, Cuba to samples of specimen of serum that were collected from people with SFI from the 6th day of the beginning of symptoms to detect antibodies IgM against Dengue using immune enzymatic test UMELISA IgM Dengue plus. Results: The results are represented in graphs from January to December 2017. Conclusions: The month of greater reactivity was October with 25.99% and the municipalities more affected were Baraguá with 20%, Ciego de Ávila with 11.99%, Morón with 11.86%, and Ciro Redondo with 11.11% of reactivity which were municipalities with transmission. The positive and negative control serum of the test was under statistic control. The concordance between the tests was 86.60% and the prevalence for the UMELISA IgM DENGUE PLUS test was 10.32%.
VL  - 10
IS  - 3
ER  -

Copy | Download

Author Information

Alvarez Maturell Elvio Luis

Department of HIV Confirmation, Provincial Hygiene, Epidemiology and Microbiology Center, Ciego of ávila, Cuba
Pérez Parrado Ileana

System Ultra Analytic Micro Laboratory, Provincial Hygiene, Epidemiology and Microbiology Center, Ciego of ávila, Cuba
Pérez Parrado Rogelio

Department of English, Máximo Gómez Báez University of Ciego of ávila, Ciego of ávila, Cuba

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Alvarez Maturell Elvio Luis, Pérez Parrado Ileana, Pérez Parrado Rogelio. (2022). Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus. International Journal of Immunology, 10(3), 25-29. https://doi.org/10.11648/j.iji.20221003.11

Copy | Download

ACS Style

Alvarez Maturell Elvio Luis; Pérez Parrado Ileana; Pérez Parrado Rogelio. Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus. Int. J. Immunol. 2022, 10(3), 25-29. doi: 10.11648/j.iji.20221003.11

Copy | Download

AMA Style

Alvarez Maturell Elvio Luis, Pérez Parrado Ileana, Pérez Parrado Rogelio. Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus. Int J Immunol. 2022;10(3):25-29. doi: 10.11648/j.iji.20221003.11

Copy | Download

@article{10.11648/j.iji.20221003.11,
  author = {Alvarez Maturell Elvio Luis and Pérez Parrado Ileana and Pérez Parrado Rogelio},
  title = {Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus},
  journal = {International Journal of Immunology},
  volume = {10},
  number = {3},
  pages = {25-29},
  doi = {10.11648/j.iji.20221003.11},
  url = {https://doi.org/10.11648/j.iji.20221003.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20221003.11},
  abstract = {Introduction: Dengue is an acute fever disease of sudden beginning, which is characterized by fever, cefalea, arthralgia, myalgia, rash, nausea, vomits and is caused by the Dengue virus that belongs to the Flaviviridae family, flavivirus genre and has four viral serotypes DEN -1, DEN - 2, DEN - 3, DEN – 4. It is transmitted by female mosquito bites from the Aedes aegypti genre and the A. albopictus. Medically, it constitutes the most important viral disease transmitted by anthropoid and the most important in terms of morbidity and mortality. Therefore, it is more important to assess the detection of antibodies IgM Dengue with immune enzymatic test UMELISA IgM Dengue plus in the surveillance of Dengue. Material and Methods: An observational study of transversal type was done from January to December 2017 in SUMA Laboratory of Advance Technology Hygiene, Epidemiology and Microbiology Provincial Center of Ciego de Ávila, Cuba to samples of specimen of serum that were collected from people with SFI from the 6th day of the beginning of symptoms to detect antibodies IgM against Dengue using immune enzymatic test UMELISA IgM Dengue plus. Results: The results are represented in graphs from January to December 2017. Conclusions: The month of greater reactivity was October with 25.99% and the municipalities more affected were Baraguá with 20%, Ciego de Ávila with 11.99%, Morón with 11.86%, and Ciro Redondo with 11.11% of reactivity which were municipalities with transmission. The positive and negative control serum of the test was under statistic control. The concordance between the tests was 86.60% and the prevalence for the UMELISA IgM DENGUE PLUS test was 10.32%.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Surveillance of Dengue with Immune Enzematic Test UMELISA IgM Dengue Plus
AU  - Alvarez Maturell Elvio Luis
AU  - Pérez Parrado Ileana
AU  - Pérez Parrado Rogelio
Y1  - 2022/10/17
PY  - 2022
N1  - https://doi.org/10.11648/j.iji.20221003.11
DO  - 10.11648/j.iji.20221003.11
T2  - International Journal of Immunology
JF  - International Journal of Immunology
JO  - International Journal of Immunology
SP  - 25
EP  - 29
PB  - Science Publishing Group
SN  - 2329-1753
UR  - https://doi.org/10.11648/j.iji.20221003.11
AB  - Introduction: Dengue is an acute fever disease of sudden beginning, which is characterized by fever, cefalea, arthralgia, myalgia, rash, nausea, vomits and is caused by the Dengue virus that belongs to the Flaviviridae family, flavivirus genre and has four viral serotypes DEN -1, DEN - 2, DEN - 3, DEN – 4. It is transmitted by female mosquito bites from the Aedes aegypti genre and the A. albopictus. Medically, it constitutes the most important viral disease transmitted by anthropoid and the most important in terms of morbidity and mortality. Therefore, it is more important to assess the detection of antibodies IgM Dengue with immune enzymatic test UMELISA IgM Dengue plus in the surveillance of Dengue. Material and Methods: An observational study of transversal type was done from January to December 2017 in SUMA Laboratory of Advance Technology Hygiene, Epidemiology and Microbiology Provincial Center of Ciego de Ávila, Cuba to samples of specimen of serum that were collected from people with SFI from the 6th day of the beginning of symptoms to detect antibodies IgM against Dengue using immune enzymatic test UMELISA IgM Dengue plus. Results: The results are represented in graphs from January to December 2017. Conclusions: The month of greater reactivity was October with 25.99% and the municipalities more affected were Baraguá with 20%, Ciego de Ávila with 11.99%, Morón with 11.86%, and Ciro Redondo with 11.11% of reactivity which were municipalities with transmission. The positive and negative control serum of the test was under statistic control. The concordance between the tests was 86.60% and the prevalence for the UMELISA IgM DENGUE PLUS test was 10.32%.
VL  - 10
IS  - 3
ER  -

Copy | Download